Exhale

The official blog of the Lung Institute.

This Week in Lung Disease: Two-Story-Tall Air Purifier Tested in China

7 Aug 2016
| Under Lifestyle | Posted by
| 1 Comment

For those having trouble finding interesting news affecting those with lung disease, have no fear. Each week, the Lung Institute searches the internet to find the latest lung disease news so you can focus on your family and health.

Smoggy Beijing Testing a 23-Foot-Tall Air Purifier

When people think of cities with terrible air pollution, Beijing is usually towards the top of the list. That’s why Chinese officials are trying something new to fight catastrophic levels of air pollution in the form of a two-story-tall Smog Free Tower.

Daan Roosegaarde, the project’s lead designer, said his 23-foot-tall tower can eliminate 70 to 80 percent of impurities in the air from an area the size of a football stadium in 36 hours. Roosegaarde will be setting up the tower in Beijing next month. Though Chinese officials don’t think this will cure all of China’s pollution problems, it serves as a way to raise awareness among citizens to help fight pollution.

For more information, check out the New York Times.

Department of Defense Grants $11.5 Million to Study Lung Disease

The Department of Defense has awarded National Jewish Health $11.5 million in grants to research and treat soldiers with lung disease. National Jewish Health, an academic medical research facility located in Denver, Colo., will be looking specifically at warfighters who were deployed to Southwest Asia.

Warfighters sent to that region come down with a wide variety of lung disease at almost twice the rate as soldiers deployed in other regions of the world. Since 2001, more than 2.8 million military personnel, contractors and non-governmental organization employees have been sent to the region, specifically Iraq and Afghanistan. Those deployed were more likely to report suffering from respiratory disease, ranging from chronic asthma to bronchiolitis obliterans.

For more information, go the PR Newswire.

Scientists Look into New Method of Boosting Cellular Production

Researchers have discovered a new method of creating human cells which can lead to understanding the cell’s potential. Currently, the study of cells has been limited due to many factors making it difficult to harvest large amounts of quality cells. This new method could lead to quicker and cheaper larger scale industrial production. This discovery was made by several scientists from the University of Nottingham, Uppsala University and GE Healthcare in Sweden.

Learn more by going to the University of Nottingham’s website.

Johnson & Johnson Developing Early Detection, Treatment Plan for COPD

Since 2015, healthcare giant Johnson & Johnson has been working on a project to learn how to predict and treat diseases in the early stages. In March, J&J gave an update on two projects stemming from this idea. One of the projects is to identify and treat people who are at risk or in the early stages of chronic obstructive pulmonary disease (COPD).

Researchers from J&J have said this project has become more feasible thanks to recent scientific advancements, including the mapping of the human genome.

For more information, go to Fox News Health.

Keep checking in with us for the latest lung disease news. If you or someone you know has a chronic lung disease, remember there is hope. At the Lung Institute, we specialize in cellular therapys for those with lung diseases such as COPD, pulmonary fibrosis and interstitial lung disease. For more information about the Lung Institute or cellular therapy, please contact one of our patient coordinators by calling (800) 729-3065 today.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.